Author(s):
Sonali Singh, Jagdish Kakadiya
Email(s):
sonaliss1230@gmail.com
DOI:
10.52711/0974-360X.2025.00316 
Address:
Sonali Singh*, Jagdish Kakadiya
Department of Pharmacology, Parul Institute of Pharmacy and Research, Parul University, Limda, Waghodia, Vadodara - 391760, Gujarat, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 5,
Year - 2025
ABSTRACT:
Alzheimer's disease is a degenerative illness that can make it difficult for a person to communicate or react to their surroundings. The ageing process is a complex one that alters a person's ability to operate normally over time. This change is causing a decline in biological functioning, particularly those related to the brain and cognition. Memory and learning impairments are mostly caused by oxidative stress, amyloid-ß buildup in the hippocampal area, and neuronal death. Thus, the aim of this research intended to evaluate the neuroprotective effects of Galantamine and/or Ferulic acid alone on rats that had Alzheimer's disease triggered by scopolamine. Followed a seven-day course of treatment with scopolamine at a dose of 1mg/kg (i.p.) to impair memory. Additionally, they were treated orally with 3mg/kg of Galantamine and 100mg/kg of Ferulic acid. It is divided into two groups: one for normal control (0.9% saline) and the other for disease control (scopolamine, 1mg/kg (i.p.) for 7 days), as well as standard groups scopolamine + Galantamine, 3mg/kg (po). The Test-1 group received scopolamine +Ferulic acid at a dose of 100mg/kg (po), while the Test-2 group received a combination of Galantamine and Ferulic acid for 21 days. At the start of the examination, all animals received physical exercise in addition to 28 days of treatment with galantamine, ferulic acid, and scopolamine. Every physical parameter was scheduled for testing on the 29th day. In comparison to the disease control group, the groups that received Galantamine and Ferulic acid (P< 0.0001) dramatically reduced the negative impact of scopolamine on the time it took to reach the favorable arm in the Y-maze. With daily treatment it shows the attenuated effect of scopolamine in rats by significantly reducing the AchE activity (p<0.0001) whereas increase in superoxide dismutase (p<0.0001). The present study confers that Galantamine with Ferulic acid possess neuroprotective effect in scopolamine induced AD in rats. It may be used as an alternative therapy strategy to treat Alzheimer's disease and improves the cognitive impairment by lowering oxidative stress.
Cite this article:
Sonali Singh, Jagdish Kakadiya. Novel Galantamine-ferulicacid hybrids: A Multi-target approach to Alzheimer’s disease. Research Journal of Pharmacy and Technology. 2025;18(5):2207-2. doi: 10.52711/0974-360X.2025.00316
Cite(Electronic):
Sonali Singh, Jagdish Kakadiya. Novel Galantamine-ferulicacid hybrids: A Multi-target approach to Alzheimer’s disease. Research Journal of Pharmacy and Technology. 2025;18(5):2207-2. doi: 10.52711/0974-360X.2025.00316 Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-5-39
REFERENCES:
1. Avhale GJ et al. Alzheimer's Diseases. Int. J. Pharm. Sci. 2023; 1(11): 507-516.
2. Trejo-Lopez JA et al. Neuropathology of Alzheimer's disease. Neurother. 2023; 19(1): 173-185.
3. Alzheimers Dement. 2022 Alzheimer's disease facts and figures. 2022; 18(4): 700-789. doi: https://doi.org/10.1002/alz.12638.
4. Shatabdi Choudhury, ChitraVellapandian. Alzheimer’s Disease Pathophysiology and its Implications. Research J. Pharm. and Tech. 2019; 12(4): 2045-2048. doi: https://doi.org/10.5958/0974-360X.2019.00338.X
5. Abduljawad AA et al. Alzheimer’s disease as a major public health concern: Role of dietary saponins in mitigating neurodegenerative disorders and their underlying mechanisms. Mol. 2022; 27(20): 6804. doi: https://doi.org/10.3390/ molecules27206804.
6. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer’s disease. Mol. Neurodegener. 2019; 14(1): 1-18. doi: https://doi.org/10.1186/s13024-019-0333-5
7. Dhinakaran S et al. Targets for Alzheimer’s disease. Research J. Pharm. and Tech. 2019; 12(6): 3073-3077. doi: https://doi.org/ 10.5958/0974-360X.2019.00521.3
8. Rahul P. Pol et al. Targeting Aβ protein in Alzheimer’s disease. Research J. Pharm. and Tech. 2020; 13(2): 1004-1008. doi: https://doi.org/10.5958/0974-360X.2020.00186.9
9. YamanaSrikanth et al. Medicinal plants Targeting Alzheimer’s disease - A Review. Research J. Pharm. and Tech. 2020; 13(7): 3454-3458. doi: https://doi.org/10.5958/0974-360X.2020.00613.7
10. Zhang Y et al. Amyloid β-based therapy for Alzheimer’s disease: Challenges, successes and future. Signal Transduct Target Ther. 2023;8(1):248. doi: https://doi.org/10.1038/s41392-023-01484-7
11. Du Xet al. Alzheimer’s disease hypothesis and related therapies. Transl. Neurodegener. 2018; 7: 1-7. doi: https://doi.org/10.1186/ s40035-018-0107-y
12. M.VijeyAanandhi et al. A Comprehensive Review on the Role of Tau Proteins in Alzheimer’s Pathology. Research J. Pharm. and Tech. 2018; 11(2): 788-790. doi: https://doi.org/10.5958/0974-360X.2018.00149.X
13. Cheignon C et al. Oxidative stress and the amyloid beta peptide in Alzheimer’s disease. Redox Biol. 2018; 14: 450-464. doi: https://doi.org/10.1016/j.redox.2017.10.014. PMID: 29080524.
14. M. VijeyAanandhi et al. A Review on the Role of Presenilin in Alzheimer’s disease. Research J. Pharm. and Tech 2018; 11(5): 2149-2151. doi: https://doi.org/10.5958/0974-360X.2018.00397.9
15. Guglielmotto M et al. Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors. Front. Aging Neurosci. 2010; 2: 1276. doi: https://doi.org/10.3389/ neuro.24.003.2010
16. García-Ayllón MS et al. Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid. Front. Mol. Neurosci. 2011; 4: 22. doi: https://doi.org/10.3389/ fnmol.2011.00022.
17. Antony Justin et al. Recent advances in the treatment of Alzheimer’s disease: An Immunotherapeutic approach. Research J. Pharm. and Tech. 2020; 13(4): 2057-2062. doi: https://doi.org/ 10.5958/0974-360X.2020.00370.4
18. Tamilselvan. M et al. Unfolding Remedial Targets for Alzheimer’s disease. Research J. Pharm. and Tech. 2020; 13(6): 3021-3027. doi: https://doi.org/10.5958/0974-360X.2020.00534.X
19. Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch Pharm Res. 2013; 36: 375-399. doi: https://doi.org/10.1007/s12272-013-0036-3
20. Wang EJ et al. Ferulic acid in animal models of Alzheimer’s disease: A systematic review of preclinical studies. Cell. 2021; 10(10): 2653. doi: https://doi.org/10.3390/cells10102653
21. DhanlaxmiPinisetti et al. Role of Quercetin as an effective Bioenhancer in Curcumin Absorption, In vitro Study. Research J. Pharm. and Tech. 2022; 15(11): 4867-0. doi: https://doi.org/ 10.52711/0974-360X.2022.00817
22. Sgarbossa A et al. Ferulic acid: a hope for Alzheimer’s disease therapy from plants. Nutrients. 2015; 7(7): 5764-5782. doi: https://doi.org/10.3390/nu7075246
23. Vybhava Krishna et al. Chronic treatment with Escitalopram Reversed Scopolamine-induced Memory Impairment by enhancing Cholinergic activity in Wistar albino Rats. Research J. Pharm. and Tech. 2021; 14(4): 1887-1892. doi: https://doi.org/ 10.52711/0974-360X.2021.00333
24. Kilari EK et al. Anti-stress and nootropic activity of aqueous extract of Piper longum fruit, estimated by noninvasive biomarkers and Y-maze test in rodents. Environ Exp Biol. 2015;13:25-31.
25. Mahdavi MR et al. The effect of food restriction on learning and memory of male Wistar rats: A behavioral analysis. Basic ClinNeurosci. 2009; 1(2): 20-23.
26. Patel C et al. Neuroprotective effect of lutein in scopolamine-induced Alzheimer’s disease in mice and zebrafish. Rev. Bras. Farmacogn. 2021; 31: 761-771.